Interleukin-17 acts as double-edged sword in anti-tumor immunity and tumorigenesis

Cytokine. 2017 Jan:89:34-44. doi: 10.1016/j.cyto.2015.09.011. Epub 2016 Feb 14.

Abstract

Interleukin-17 (IL-17), a proinflammatory cytokine, mainly produced by Th17 cells, participates in both innate and adaptive immune responses and is involved in various diseases, including infectious diseases, autoimmune disorders and cancer. Emerging evidence indicates that IL-17 not only has an oncogenic role in tumorigenesis by regulating tumor angiogenesis and enhancing tumor immune evasion but also exerts anti-tumor functions by enhancing natural killer (NK) cells and cytotoxic T lymphocytes (CTLs) activation and through the recruitment of neutrophils, NK cells and CD4+ and CD8+ T cells to tumor tissue. In this review, we provide an overview on the basic biology of IL-17 and recent findings regarding its enigmatic double-edged features in tumorigenesis, with special attention to the roles of IL-17 produced by tumor cells interacting with other factors in the tumor microenvironment.

Keywords: Angiogenesis; Cytokine; Interleukin (IL)-17; Tumor immunity; Tumorigenesis.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • CD8-Positive T-Lymphocytes / immunology*
  • CD8-Positive T-Lymphocytes / pathology
  • Humans
  • Immunity, Cellular*
  • Interleukin-17 / immunology*
  • Killer Cells, Natural / immunology*
  • Killer Cells, Natural / pathology
  • Receptors, Antigen, T-Cell, gamma-delta / immunology
  • Th17 Cells / immunology*
  • Th17 Cells / pathology
  • Tumor Microenvironment / immunology*

Substances

  • Interleukin-17
  • Receptors, Antigen, T-Cell, gamma-delta